Emergings In Brief, May 2015
This article was originally published in Start Up
Executive Summary
Brief profiles of these recently formed companies: Admera Health, Denali Therapeutics, Esperas Pharma, and OccuRx.
You may also be interested in...
Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m
Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.
In Vivo's Deals Of The Month, February 2018
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)
In Vivo's Deals Of The Month, January 2018
In Vivo's editors pick January's most significant deals, including an alliance of players new to health care and Celgene's big buys. (Free article.)